Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Mullins JI, Heath L, Hughes JP, Kicha J, Styrchak S, Wong KG, Rao U, Hansen A, Harris KS, Laurent JP, Li D, Simpson JH, Essigmann JM, Loeb LA, Parkins J.

PLoS One. 2011 Jan 14;6(1):e15135. doi: 10.1371/journal.pone.0015135.

2.

Tautomerism provides a molecular explanation for the mutagenic properties of the anti-HIV nucleoside 5-aza-5,6-dihydro-2'-deoxycytidine.

Li D, Fedeles BI, Singh V, Peng CS, Silvestre KJ, Simi AK, Simpson JH, Tokmakoff A, Essigmann JM.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3252-9. doi: 10.1073/pnas.1405635111. Epub 2014 Jul 28.

3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Safety, tolerability, and efficacy of KP-1461 as monotherapy for 124 days in antiretroviral-experienced, HIV type 1-infected subjects.

Hicks C, Clay P, Redfield R, Lalezari J, Liporace R, Schneider S, Sension M, McRae M, Laurent JP.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):250-5. doi: 10.1089/AID.2012.0093. Epub 2012 Aug 27.

6.

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM.

J Clin Microbiol. 2005 Jan;43(1):406-13.

7.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
8.

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC.

Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905.

9.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

10.
11.
12.

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.

PMID:
11448283
13.
14.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.

PLoS Med. 2007 Dec;4(12):e335.

15.

Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.

Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper DA, Cox S.

HIV Med. 2011 Jul;12(6):334-42. doi: 10.1111/j.1468-1293.2010.00887.x. Epub 2010 Nov 3.

16.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
17.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
18.
19.

Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

Günthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD.

J Virol. 1998 Mar;72(3):2422-8.

20.

Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, Segondy M.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):36-43. Erratum in: J Acquir Immune Defic Syndr 2001 Apr 1;26(4):395.

PMID:
11176267

Supplemental Content

Support Center